These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 12389064)

  • 1. Efficacy and dangers of statin therapy.
    Maritz FJ
    Cardiovasc J S Afr; 2002; 13(4):200-3. PubMed ID: 12389064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Statins and their pleiotropic effects].
    Galus R; Zandecki Ł; Jóźwiak J; Włodarski K
    Pol Merkur Lekarski; 2008 Jun; 24(144):545-8. PubMed ID: 18702340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-atherosclerotic effects of statins: lessons from prevention trials.
    Ganesh SK; Nass CM; Blumenthal RS
    J Cardiovasc Risk; 2003 Jun; 10(3):155-9. PubMed ID: 12775947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical trials on protective efficacy of statins for cardiovascular events due to hyperlipidemia (J-LIT, 4S, CARE, LIPID etc)].
    Higashikata T
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():628-36. PubMed ID: 15171447
    [No Abstract]   [Full Text] [Related]  

  • 5. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
    Kłosiewicz-Latoszek L; Respondek W; Białobrzeska-Paluszkiewicz J; Grzybowska B; Jakóbisiak-Ostasz B; Stolarska I
    Pol Merkur Lekarski; 2003 Jul; 15(85):42-6. PubMed ID: 14593958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal medical management of peripheral arterial disease.
    Rice TW; Lumsden AB
    Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dyslipidaemia.
    Durrington P
    Lancet; 2003 Aug; 362(9385):717-31. PubMed ID: 12957096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statin pleiotropy: fact or fiction?
    Futterman LG; Lemberg L
    Am J Crit Care; 2004 May; 13(3):244-9. PubMed ID: 15149060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of lipid disorders for coronary heart disease prevention according to International Atherosclerosis Society recommendations].
    Idzior-Waluś B
    Przegl Lek; 1999; 56(5):372-6. PubMed ID: 10554575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [What other effects do statins have except their effect on lipids?].
    Tikkanen MJ
    Duodecim; 1998; 114(13):1299-301. PubMed ID: 11552256
    [No Abstract]   [Full Text] [Related]  

  • 11. The efficacy and safety of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in chronic kidney disease, dialysis, and transplant patients.
    Olyaei A; Greer E; Delos Santos R; Rueda J
    Clin J Am Soc Nephrol; 2011 Mar; 6(3):664-78. PubMed ID: 21393488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction?
    Comparato C; Altana C; Bellosta S; Baetta R; Paoletti R; Corsini A
    Nutr Metab Cardiovasc Dis; 2001 Oct; 11(5):328-43. PubMed ID: 11887430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Atherosclerosis and simvastatin: new questions for the new millennium].
    Tubaro M; Guido V; Sciarra L; Mustilli M; Carbone MA; D'Errico F
    Ann Ital Med Int; 2000; 15(1):108-14. PubMed ID: 10842900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?
    März W; Köenig W
    J Cardiovasc Risk; 2003 Jun; 10(3):169-79. PubMed ID: 12775949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prevention and therapy of vascular damage and endothelial dysfunction with hypocholesteremic agents].
    De Caterina R; Lenzi S
    G Ital Cardiol; 1998 Feb; 28(2):168-77. PubMed ID: 9534058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The pleiotropic effects of statins].
    Wolfovitz E
    Harefuah; 2005 Aug; 144(8):577-82, 597. PubMed ID: 16146158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The power of statins: aggressive lipid lowering.
    Jones PH
    Postgrad Med; 2002 Oct; 112(4 Suppl):23-30. PubMed ID: 19667597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary prevention trials: lessons learned about treating high-risk patients with dyslipidemia without known cardiovascular disease.
    Ferdinand KC
    Curr Med Res Opin; 2005 Jul; 21(7):1091-7. PubMed ID: 16004678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical significance of primary and secondary prevention trials with lipid-lowering therapy against coronary heart disease].
    Sakai N; Yamashita S
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():365-73. PubMed ID: 11347096
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis.
    Petretta M; Costanzo P; Perrone-Filardi P; Chiariello M
    Int J Cardiol; 2010 Jan; 138(1):25-31. PubMed ID: 18793814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.